Bayesian Capital Management’s GSK GSK Stock Holding History

Bayesian Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,295	Closed	-$444K	–	298
2025 Q3	$444K	Buy	+10,295	New	+$402K	0.09%	301
2025 Q2	–	Sell	-15,837	Closed	-$614K	–	679
2025 Q1	$614K	Buy	15,837 +1,800	+13%	+$65.9K	0.1%	260
2024 Q4	$475K	Buy	+14,037	New	+$505K	0.06%	383
2023 Q3	–	Sell	-10,500	Closed	-$374K	–	816
2023 Q2	$374K	Buy	+10,500	New	+$377K	0.04%	480
2023 Q1	–	Sell	-24,320	Closed	-$855K	–	911
2022 Q4	$855K	Sell	24,320 -27,000	-53%	-$899K	0.12%	219
2022 Q3	$1.51M	Buy	+51,320	New	+$1.95M	0.31%	74
2021 Q2	–	Sell	-27,860	Closed	-$1.24M	–	500
2021 Q1	$1.24M	Buy	+27,860	New	+$1.26M	0.29%	89
2016 Q3	–	Sell	-5,584	Closed	-$303K	–	409
2016 Q2	$303K	Buy	5,584 +1,032	+23%	+$54.4K	0.18%	233
2016 Q1	$231K	Sell	4,552 -1,345	-23%	-$67K	0.22%	238
2015 Q4	$297K	Buy	+5,897	New	+$301K	0.43%	101

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bayesian Capital Management's GSK Position: Q4 2025 in Review

Bayesian Capital Management sold out of GSK (GSK) in Q4 2025, closing a stake of 10,295 shares — an estimated $444K sold.

Bayesian Capital Management first reported a position in GSK in Q4 2015 and held it in 10 quarters. The position peaked at $1.51M in Q3 2022. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Bayesian Capital Management reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 10,295 GSK shares in Q4 2025, an estimated $444K.
Bayesian Capital Management first reported a position in GSK in Q4 2015 and held it in 10 quarters.
Bayesian Capital Management's GSK position peaked at $1.51M in Q3 2022.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.